276251-83-3

Usage

Uses

Used in Organic Synthesis:
2-Bromo-4,6-dimethoxy-pyridine is utilized as a versatile building block for the preparation of various pharmaceuticals, agrochemicals, and functional materials. Its unique structure and reactivity make it a valuable component in the synthesis of a wide range of organic compounds.
Used in Heterocyclic Compounds Synthesis:
2-BroMo-4,6-diMethoxy-pyridine also serves as a reagent in the synthesis of heterocyclic compounds, which are essential in various chemical and pharmaceutical applications due to their diverse properties and functions.
Used as a Precursor in Production of Other Organic Compounds:
Furthermore, 2-bromo-4,6-dimethoxy-pyridine is employed as a precursor in the production of other organic compounds, highlighting its significance in expanding the scope of organic chemistry and contributing to the development of new materials and substances.

Upstream product

• 124-41-4 sodium methylate 
• 175422-04-5 2,6-dibromo-4-nitropyridine 
• 98027-81-7 2,6-dibromo-4-nitro-pyridine 1-oxide 
• 25373-69-7 2,6-dibromopyridin N-oxide 
• 626-05-1 2,6-Dibromopyridine 
• 2408-70-0 2,4,6-tribromopyridine 

Downstream Products

• 18677-43-5 2,4-dimethoxypyridine 

Relevant academic research and scientific papers

Inhibition of cancer-associated mutant isocitrate dehydrogenases: Synthesis, structure-activity relationship, and selective antitumor activity

Mutations of isocitrate dehydrogenase 1 (IDH1) are frequently found in certain cancers such as glioma. Different from the wild-type (WT) IDH1, the mutant enzymes catalyze the reduction of α-ketoglutaric acid to d-2-hydroxyglutaric acid (D2HG), leading to cancer initiation. Several 1-hydroxypyridin-2-one compounds were identified to be inhibitors of IDH1(R132H). A total of 61 derivatives were synthesized, and their structure-activity relationships were investigated. Potent IDH1(R132H) inhibitors were identified with Ki values as low as 140 nM, while they possess weak or no activity against WT IDH1. Activities of selected compounds against IDH1(R132C) were found to be correlated with their inhibitory activities against IDH1(R132H), as well as cellular production of D2HG, with R2 of 0.83 and 0.73, respectively. Several inhibitors were found to be permeable through the blood-brain barrier in a cell-based model assay and exhibit potent and selective activity (EC50 = 0.26-1.8 μM) against glioma cells with the IDH1 R132H mutation.